A Phase 2 interventional study of Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha) and 9-valent HPV vaccine(Gardasil 9) in HPV Infection and HPV-Related Cervical Carcinoma, sponsored by National Vaccine and Serum Institute, China. Completed at 1 site in China. Open to female participants aged 18 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-06.
Sponsored by National Vaccine and Serum Institute, China (part of Sinopharm) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Papillomavirus Infections with a site in China — 23 open to participants now, 36 under way, 10 of them phase 3. Papillomavirus Infections · China.
Among the 65 studies in Papillomavirus Infections with a site in China, this one is the 23rd largest by enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2020, is one of 7 in phase 2, and was the 18th registered.
577 studies on the registry are indexed under Papillomavirus Infections; 131 are open to participants now.
Browse Papillomavirus Infections studies →23 of the 65 studies in Papillomavirus Infections with a site in China are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in China
Ages 10–45 · Women only · Healthy volunteers
Shanghai Mianyi Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Women only
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 25–65 · Women only · Healthy volunteers
The First Hospital of Jilin University · Sites in China
Ages 26–65 · Women only
Shanghai Bovax Biotechnology Co., Ltd. · Sites in China
Ages 9–45 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 85 Papillomavirus Infections studies recruiting now, 38 (45%) set no upper age limit and 42 (49%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 26 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 18 · Phase 4 3
First in 2005; this study’s year is marked. 6 started in 2020.
This study's enrollment of 480 is above the median of 235 across 402 interventional studies indexed under Papillomavirus Infections.
Median enrollment 550 across the 42 interventional studies, 2,200 across the 23 observational. Of the 18 that completed or were terminated, 5 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 65 have an industry lead sponsor. The 10 most frequent:
This study is registered under National Vaccine and Serum Institute, China, one of the names counted as Sinopharm. Under that name alone:
National Vaccine and Serum Institute, China is the lead sponsor of 13 studies on the registry; none are open to participants now.
Sinopharm has 4 studies filed under Papillomavirus Infections — fewer than ten, so there is no comparison to draw.
4 of the studies in Papillomavirus Infections with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07833852Shanghai Zerun Biotechnology Co.,LtdLong-Term Immune Persistence After Bivalent HPV Vaccination in Females From Study 311-HPV-1005 | 2026-12 |
| NCT06137352Fujian Maternity and Child Health HospitalTwo Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity | 2026-12-31 |
| NCT07820241Shanghai Zerun Biotechnology Co.,LtdLong-term Immune Persistence of a Bivalent HPV Vaccine in Females From Study 311-HPV-1004 | 2027-04 |
| NCT05371353Shanghai Bovax Biotechnology Co., Ltd.Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine | 2027-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 65 studies in Papillomavirus Infections with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A total of 480 Chinese women aged 18-26 years old were enrolle,experimental group and the control group were randomly assigned in a ratio of 3:1. 360 Chinese women in the experimental group and 120 in the control group. All subjects enrolled in the upper arm deltoid muscle were injected with 3 doses of test vaccine or control vaccine according to the 0, 2, and 6 months immunization program.
Inclusion Criteria:
First dose exclusion criteria:
12.Body temperature before inoculation≥37.3℃(armpit body temperature); 13. People who have a systolic blood pressure ≥140mmHg and/or a diastolic blood pressure ≥90mmHg before enrollment; 14. Participate or plan to participate in other clinical trials (drugs, vaccines and medical devices) during the study; 15. Plan to move out of the local area before the end of the study or leave the area for a long time during the scheduled study visit;
Exclusion criteria for second and third doses of vaccination:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
Biological: 9-valent HPV vaccine(Gardasil 9)
Drug pages: Biological Products · Recombinant Human Papillomavirus 11-valent Vaccine
Inject vaccine produced by ChinaVaccineSerum, containing HPV antigen protein, 270μg/1ml per bottle
Inject Gardasil 9 , containing HPV antigen protein, 270μg/0.5ml per bottle
Anti-HPV neutralizing antibodies GMT
Time frame: 30 days after full immunization
Anti-HPV neutralizing antibody positive conversion rate(after full immunization 30 days)
Time frame: 30 days after full immunization
Collect all SAEs
Vaccine-related and unrelated
Time frame: through study completion, an average of 13 months
Collect AEs incidence
Vaccine-related and unrelated
Time frame: Within 30 minutes of injection
Collect AEs incidence
All AEs: incidence of AEs related to vaccines and unrelated The rate of Solicited for AE Non-collective AEs: incidence of AEs related to vaccines and unrelated AE level 3 and above: incidence of vaccine-related and unrelated AEs
Time frame: Within 30 days after inoculation
collect AEs leading subject to withdrawal
Incidence of vaccine-related and unrelated AEs
Time frame: through study completion, an average of 13months
collect All pregnancy conditions and pregnancy outcomes
collect pregnant woman Anti-HPV neutralizing antibody positive conversion rate and Anti-HPV neutralizing antibodies GMT
Time frame: through study completion, an average of 13 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2020 to primary completion in Mar 2022, 20 months.
Of 41 phase 2 interventional studies under Papillomavirus Infections, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 77. This study's 20 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Biological Products · Recombinant Human Papillomavirus 11-valent Vaccine
National Vaccine and Serum Institute, China →